Skip to main content

MiniMed Group, Inc.

MMED
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0002062583

No open-market purchases or sales by MiniMed Group, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q3 2026, worth $1.14B in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 3:21 PM ET

Revenue flow, FY2026

Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2026: $333.0M (10.7% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of MiniMed Group, Inc., annual
Line itemFY2026
Period endApr 24, 2026
Filing10-K
ReportedJun 3, 2026
Revenue$3.10B
Cost of revenue$1.42B
Gross profit$1.68B
Research and development$448.0M
Selling, general and administrative$1.18B
Operating income-$190.0M
Income tax$128.0M
Net income-$333.0M
EPS, basic$-1.30
EPS, diluted$-1.30
Weighted shares, basic256.6M
Weighted shares, diluted256.6M
Margins and growth
Gross margin54.2%
Operating margin-6.1%
Net margin-10.7%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of MiniMed Group, Inc., annual
Line itemFY2026
Period endApr 24, 2026
Filing10-K
ReportedJun 3, 2026
Cash and equivalents$298.0M
Accounts receivable$200.0M
Inventory$341.0M
Total current assets$1.35B
Property, plant and equipment$711.0M
Goodwill$2.26B
Intangible assets$107.0M
Total assets$4.63B
Accounts payable$163.0M
Total current liabilities$702.0M
Total liabilities$1.02B
Shareholders' equity$3.61B

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of MiniMed Group, Inc., annual
Line itemFY2026
Period endApr 24, 2026
Filing10-K
ReportedJun 3, 2026
Operating cash flow-$197.0M
Capital expenditures$223.0M
Free cash flow-$420.0M
Depreciation and amortization$156.0M
Stock-based compensation$46.0M
Investing cash flow-$233.0M
Financing cash flow$716.0M
Net change in cash$287.0M
Ratio
Stock-based compensation, % of revenue1.5%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for MiniMed Group, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Sep 3, 2026281.3M–SEC
Jun 19, 2026280.8M–SEC
Apr 11, 2026280.8M–SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.